Evidence Based Medicine

1
Evidence Based Medicine

• PGY1 ???

2
General Data

• Patient?xx
• Chart Number X
• Gender male
• Age 42 year-old
• Married status married.
• Occupation ???

3
Present Illness

• Fever for 3 days
• Headache, sorethroat, muscle soreness, dry cough
• Throat swab Influenza type A

4
Critical Appraisal Topics
5
Three-part Clinical Question

• Patient/problem
• Patient who has influenza type A and type B
• Intervention
• Oseltamivir
• Comparison
• Zanamivir
• Outcomes
• Duration of fever
• The percentage of patients afebrile at 24 hrs and
  48hrs after the first dose of Oseltamvir or
  Zanamivir
• Type of Question
• Therapy

6
Title

• A comparison of the effectiveness of zanamivir
  and oseltamivir for the treatment of influenza A
  and B.

7
Clinical bottom line

• Zanamivir therapy is more effective than
  oseltamivir for the treatment of influenza B
  infection.

8
Citation/s

• A comparison of the effectiveness of zanamivir
  and oseltamivir for the treatment of influenza A
  and B
• Journal of Infection (2008) 56, 51e57

9
Lead author's name

• Naoki Kawai , Hideyuki Ikematsu , Norio Iwaki ,
  Tetsunari Maeda , Hideo Kanazawa , Takashi
  Kawashima , Osame Tanaka, Satoshi Yamauchi ,
  Kenichi Kawamura, Toru Nagai a, Satsuki Horii,
  Nobuo Hirotsu, Seizaburo Kashiwagi nsultant

10
Search Terms Strategy
11
Search Terms Strategy

12
Introduction

• The effectiveness of zanamivir, another
  neuraminidase inhibitor, has been reported, but
  it has not been compared fully between influenza
  A and influenza B, except for our recent
  preliminary report on a small number of
  patients..

13
Materials Methods
control
14
Results
15
Results
16
(No Transcript)
17
Discussion

• In conclusion, zanamivir is more effective than
  oseltamivir for the treatment of influenza B.
• Zanamivir is the most effective neuraminidase
  inhibitor for the treatment of influenza B in
  children over four years and adults.
• Limitation
• Our study in that it was performed in a
  general practice setting and not in the context
  of a rigorous clinical protocol
• .

18
Thanks for Your Attention!!